SYNCORDIS-S.A.
14.5.2019 12:02:02 CEST | Business Wire | Press release
Syncordis S.A., a wholly owned subsidiary of Larsen & Toubro Infotech (LTI), today announced a strategic global partnership with Temenos, the banking software company. This partnership will enable Syncordis to seamlessly offer an array of Temenos certified services to banks across the globe.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190514005422/en/
Equipped with an exclusive focus and comprehensive expertise, Syncordis has established itself as a specialist in implementation of Temenos T24 Transact, the next generation platform for core banking and Temenos WealthSuite. Through the global partnership, Syncordis will attain enhanced capabilities to offer a wide range of services across Temenos product portfolio and manage migration, training, testing and upgrade requirements of Temenos clients worldwide.
Guillaume Desjonqueres, CEO, Syncordis said, “We are excited to partner with Temenos, the market leader in cloud-native, cloud-agnostic banking software, and confident that we will be able to deliver outstanding services and experiences to our customers through this strategic alliance.”
Nachiket Deshpande, COO, LTI said, “As the Financial Services industry undergoes transformation, organizations must co-innovate to solve tough problems for their customers. Syncordis and LTI will partner with Temenos to address this demand, deliver innovation and improve business performance for our global clients in the Banking and Wealth Management space.”
Neal McLoughlin, Head of Partners & Operations, Temenos, said, “At Temenos, we understand the power of partnerships and we have built the most dynamic community in the banking industry. We are delighted to expand our partnership with Syncordis to a global strategic alliances and value their commitment. Together, we will leverage the power of our cloud-native, cloud-agnostic banking software to transform the banking industry.”
Syncordis has developed industry-leading accelerators that help with faster and consistent Temenos implementations and capture the fast-growing market opportunities for banking modernization services. This partnership will establish Syncordis as a trusted Temenos partner for end-to-end implementation, platform upgrades and enhancements for performance tuning.
About Syncordis:
Syncordis S.A., a Luxembourg based LTI Company, delivers high-quality end-to-end implementation and system integration projects with an exclusive focus on Temenos banking software. With 12 offices across the globe and 300+ experts, Syncordis enables its international clients to master their digital transformation and succeed in this ever-changing market. Having recently merged with NIELSEN+PARTNER, Syncordis now combines the business and technical expertise and experience of 15+ years in Temenos T24 Transact and SaaS solutions and production support services with 24+ years in Temenos WealthSuite, Temenos Infinity and DataSource. This makes Syncordis one of the wealth management specialists and one-stop partners for Temenos clients worldwide. For more information please visit www.syncordisconsulting.com .
About Temenos:
Temenos AG (SIX: TEMN), headquartered in Geneva, is the world’s leader in banking software, partnering with banks and other financial institutions to transform their businesses and stay ahead of a changing marketplace. Over 3,000 firms across the globe, including 41 of the top 50 banks, rely on Temenos to process both the daily transactions and client interactions of more than 500 million banking customers. Temenos offers cloud-native, cloud-agnostic front office and core banking, payments, fund management and wealth management software products enabling banks to deliver consistent, frictionless customer journeys and gain operational excellence. Temenos customers are proven to be more profitable than their peers: over a seven-year period, they enjoyed on average a 31% higher return on assets, a 36% higher return on equity and an 8.6 percentage point lower cost/income ratio than banks running legacy applications. For more information please visit www.temenos.com .
About LTI:
Larsen & Toubro Infotech (NSE: LTI, BSE: 540005) is a global technology consulting and digital solutions Company helping more than 300 clients succeed in a converging world. With operations in 30 countries, we go the extra mile for our clients and accelerate their digital transformation with LTI’s Mosaic platform enabling their mobile, social, analytics, IoT and cloud journeys. Founded in 1997 as a subsidiary of Larsen & Toubro Limited, our unique heritage gives us unrivalled real-world expertise to solve the most complex challenges of enterprises across all industries. Each day, our team of more than 28,000 LTItes enable our clients to improve the effectiveness of their business and technology operations, and deliver value to their customers, employees and shareholders. Find more at www.Lntinfotech.com or follow us at @LTI_Global.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190514005422/en/
Contact:
Media Contact for Syncordis: Clara Bechler Marketing & Communication T +49 40 369 835-12 E cbechler@syncordisconsulting.com Media Contacts for Temenos: Jessica Wolfe Temenos Global Public Relations T +1 610 232 2793 E press@temenos.com Alistair Kellie & Andrew Adie Newgate Communications on behalf of Temenos T +44 20 7680 6550 E allnewgatetemenos@newgatecomms.com Media Contacts for LTI: Neelian Homem PR & Media Relations – India T +91 900 434-5540 E neelian.homem@lntinfotech.com Karin Bakis PR & Media Relations – India T +1 978 998-1578 E karin.bakis@lntinfotech.com
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Yubico Appoints Poupak Modirassari Enbom as Chief Marketing Officer to Accelerate Global Momentum and Drive Market Leadership30.3.2026 15:00:00 CEST | Press release
Yubico (NASDAQ STOCKHOLM: YUBICO), the creator of the most secure passkeys and a leading provider of hardware authentication security keys, today announced the appointment of Poupak Enbom as Chief Marketing Officer (CMO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330278027/en/ Enbom joins Yubico at a pivotal moment as organizations worldwide accelerate the shift to phishing-resistant authentication and modern identity security in the age of AI. “We’re excited to welcome Poupak to Yubico,” said Jerrod Chong, acting chief executive officer, Yubico. “As the threat landscape evolves with AI-driven attacks and increasing automation, organizations are rethinking how they secure digital identities of both humans and AI agents at scale. She brings a unique combination of technical depth, global leadership, and customer-first mindset that will help us continue to expand our impact and support our customers and partners around
Westinghouse Celebrates Record-breaking 80 Years of Nuclear Fuel Manufacture at Springfields30.3.2026 14:00:00 CEST | Press release
Fuel manufactured at Springfields has generated enough energy to supply the UK’s electricity demand for 26 years, avoiding the emission of nearly 3 billion tonnes of CO2 The Westinghouse Springfields facility in Lancashire, UK, has marked a significant milestone as the oldest continuous nuclear fuel manufacturing site in the world, starting from its original license on the 28th, March 1946. The site was chosen by the UK Government to develop nuclear fuel for the world’s earliest civil nuclear power stations, as well as subsequent Magnox and Advanced Gas Reactors (AGR) reactors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330135973/en/ From left to right: Sophie Lemaire; Marc Chevrel; Rory O'Neill; Craig Boothby; and Robert Gofton, CEO at Nuclear Institute Across the last eight decades, the Springfields site has supported the UK nuclear fleet, manufacturing more than eight million AGR pins, sintering and pressing over 5
HistoSonics Treats First Patients Evaluating the Edison® Histotripsy System for the Treatment of Benign Prostatic Hyperplasia (BPH)30.3.2026 14:00:00 CEST | Press release
HistoSonics, the developer of the Edison® Histotripsy System and novel histotripsy therapy platform, today announced the successful treatments of the first patients in WOLVERINE, a prospective feasibility trial evaluating the Edison® Histotripsy System for the treatment of benign prostatic hyperplasia (BPH) at Prince of Wales Hospital in Hong Kong, a teaching hospital for The Chinese University of Hong Kong. The Edison System is a novel, non-invasive, image guided platform that uses the mechanical properties of focused ultrasound, called histotripsy, to destroy unwanted tissue without the need for invasive procedures, and with potentially fewer side effects than traditional, invasive therapies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330349844/en/ HistoSonics Non-Invasive Edison Histotripsy System. Image credit: HistoSonics WOLVERINE is a prospective, multi-center, single-arm feasibility trial designed to evaluate
Biocytogen Grants Taisho Pharmaceutical a License to its RenNano® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 13:00:00 CEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro
Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom